Formerly the President and COO of Rosetta, Brad helped grow the company from $115M to $225M before its sale to Publicis. Before Rosetta, He served as COO for Brulant and also held senior executive positions at several other startups including bioinformatics company Acero.
Dr. Laden co-founded TriStar Technology Ventures in 2009, and serves on the board for Molecular Sensing and the Advisory Board for Cumberland Emerging Technologies. He also holds an observer seat on the boards of TVA and BioStable in addition to GenomOncology's board.
A nationally recognized leader in innovations in health care, Jonathan “Jack” Lord, M.D, is actively engaged in driving change in healthcare through new technologies and therapies. Dr. Lord is a board-certified forensic pathologist and Fellow of the College of American Pathologists.
Len is Chairman and CEO of Next Sparc, LLC, which invests in emerging Internet-based, software and services-based companies and helps them achieve significant growth. In addition, Len was the former Vice Chairman of Rosetta and the former Chairman, CEO and founder of Brulant, Inc.
Jeff currently serves as the CEO of 1Password. Shiner has significant experience in software development, security, rapid growth, and innovation. Previously, Shiner was the Senior Development Manager of WebSphere Commerce at IBM Canada, and led a 400-person technology division at Rosetta.
